Skip to main content
APP Pearls “When seeing a new patient, never assume that their preconceived or prior diagnosis is the only rheumatolog

Dr. John Cush RheumNow

9 months ago
APP Pearls “When seeing a new patient, never assume that their preconceived or prior diagnosis is the only rheumatology condition that they have” - Lindsay Tom, PA-C
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology?

Recent large-scale clinical trials have broade

Dr. John Cush RheumNow

9 months ago
Best of 2025: Antifibrotics - A New Class of Therapies in Rheumatology? Recent large-scale clinical trials have broadened therapeutic options for SARD-ILD beyond immunosuppressants, offering new hope for patients with these serious conditions. https://t.co/RLlOdEWTOa https://t.co/UI9cdJ5Ovd
Pregnancy in SLE gets a lot of press in the rheumatology literature, and deservedly so, since pregnancy risks can be markedly increased. It was not that many years ago that women with SLE were counseled to avoid pregnancy.
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest res

Dr. John Cush RheumNow

9 months ago
NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA. Click to see the latest results from a Phase 3 trial presented at ACR 2025, sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/Tm8m43ZXBM https://t.co/GWLPR5y3d2
Nearly 25 years ago, while lecturing on best therapies for rheumatoid arthritis (RA), I loudly stated that hydroxychloroquine was “useless” and, deservedly, I was “boo-ed” off stage. My point then was that rheumatologists needed to be aggressive, if not overly aggressive, in treating all RA patients. And my view was that HCQ was representative of under-treatment. I have reconsidered the use of HCQ in RA substantially in the last few years, based
2025 ACR Guideline for the Treatment of SLE

The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment

Dr. John Cush RheumNow

9 months ago
2025 ACR Guideline for the Treatment of SLE The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE. https://t.co/2NFwTllLZa https://t.co/S7Cwzbgnde
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Gre

Dr. John Cush RheumNow

9 months ago
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 https://t.co/yzQVt1fLKW https://t.co/hrbEeppZhW
APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and

Dr. John Cush RheumNow

9 months ago
APP Pearls “Point out to every patient with gout that poorly controlled gout will increase their risk of CV events and mortality” - Emma Bavage, NP
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill

Dr. John Cush RheumNow

9 months ago
“Success is not final, failure is not fatal: it is the courage to continue that counts.” – Winston Churchill
Best of 2025: Methotrexate intolerance in rheumatoid arthritis

Methotrexate (MTX) is the most commonly used DMARD in r

Dr. John Cush RheumNow

9 months ago
Best of 2025: Methotrexate intolerance in rheumatoid arthritis Methotrexate (MTX) is the most commonly used DMARD in rheumatoid arthritis (RA); however, there is significant intolerance to this drug among adult RA patients - especially at doses above 15 mg per week. https://t.co/hzfF7UVKVI
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis

The FDA has approved nerandomilast (Jascayd), a PDE4b in

Dr. John Cush RheumNow

9 months ago
Nerandomilast FDA Approved for Progressive Pulmonary Fibrosis The FDA has approved nerandomilast (Jascayd), a PDE4b inhibitor, to treat adults with progressive pulmonary fibrosis (PPF). Nerandomilast was approved to treat idiopathic pulmonary fibrosis (IFP) in October 2025. https://t.co/KacbtcMn5G
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsi

Dr. John Cush RheumNow

9 months ago
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/PTJPhcvnzC
Best of 2025: Overview of the VEXAS Syndrome

A current systematic review in Rheumatology addresses the clinical featur

Dr. John Cush RheumNow

9 months ago
Best of 2025: Overview of the VEXAS Syndrome A current systematic review in Rheumatology addresses the clinical features seen in the VEXAS syndrome. https://t.co/O3BoOElcbT https://t.co/0hSEWqMFVf
×